Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: A case series by Iorio, A. et al.
This is a repository copy of Natural history and clinical characteristics of inhibitors in 
previously treated haemophilia A patients: A case series.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/109718/
Version: Accepted Version
Article:
Iorio, A., Barbara, A., Makris, M. orcid.org/0000-0001-7622-7939 et al. (21 more authors) 
(2017) Natural history and clinical characteristics of inhibitors in previously treated 
haemophilia A patients: A case series. Haemophilia, 23 (2). pp. 255-263. ISSN 1351-8216 
https://doi.org/10.1111/hae.13167
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
1 
 
KƌŝŐŝŶĂůƌƚŝĐůĞ 1 
 2 
dŝƚůĞ 3 
Natural history and clinical characteristics of inhibitors in previously treated haemophilia A 4 
patients: A case series  5 
 6 
ƵƚŚŽƌƐ  7 
Iorio, Alfonso
1
,
 
Angela M. Barbara
1
, Michael Makris
2
, Kathelijn Fischer
3
, Giancarlo 8 
Castaman
4
, Cristina Catarino
5
, Estelle Gilman
2
, Kaan Kavakli
6
, Thierry Lambert
7
, Riitta 9 
Lassila
8
, Toshko Lissitchkov
9
, Evelien Mauser-Bunschoten
3
, María E. Mingot-Castellano
10
, 10 
Nihal Ozdemir
11
, Ingrid Pabinger
12
, Rafael Parra
13
, John Pasi
14
, Kathelijne Peerlinck
15
, 11 
Antoine Rauch
16
, Valérie Roussel-Robert
17
, Margit Serban
18
, Annarita Tagliaferri
19
, Jerzy 12 
Windyga
20
, Ezio Zanon
21
  13 
 14 
ƵƚŚŽƌĂĨĨŝůŝĂƚŝŽŶƐ 15 
1 
Department of Clinical Epidemiology and Biostastics, McMaster University, Hamilton, 16 
Ontario, Canada; 17 
2 
Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, 18 
Sheffield, United Kingdom; 19 
3
 Van Creveldkliniek University Medical Centre Utrecht, Utrecht, The Netherlands; 20 
4 
San Bortolo Hospital, Vicenza, Italy; 21 
  
2 
 
5 
Congenital Coagulopathies Centre, Santa Maria Hospital, Lisbon, Portugal; 22 
6 
Department of Pediatric Hematology, Ege University ŚŝůĚƌĞŶ ?ƐHospital, Izmir, Turkey; 23 
7
 Centre de traitement des Hemophiles de Bicetre, Paris, France; 24 
8 
Department of Hematology, Cancer Center,
 
Helsinki University Hospital, Helsinki, Finland; 25 
9 ,ĂĞŵĂƚŽůŽŐǇ,ŽƐƉŝƚĂů “:ŽĂŶWĂǀĞů ? ?^ŽĨŝĂ ?ƵůŐĂƌŝĂ ? 26 
10 
Regional University Hospital of Málaga, Málaga, Spain; 27 
11 
Istanbul University Haemophilia Centre, Istanbul, Turkey; 28 
12
 Haemophilia Centre, Department of Medicine I, Medical University of Vienna, Vienna, 29 
Austria; 30 
13
 ,ŽƐƉŝƚĂůsĂůůĚ ?,ĞďƌŽŶ ?Barcelona, Spain; 31 
14
 Barts and the London School of Medicine, , London, United Kingdom; 32 
15 
Haemophilia Center, Universitaire Ziekenhuis Gasthuisberg,
 
Leuven, Belgium 33 
16 ĠƉĂƌƚĞŵĞŶƚĚ ?,ĠŵĂƚŽůŽŐŝĞdƌĂŶƐĨƵƐŝŽŶ ?ĞŶƚƌĞ,ŽƐƉŝƚĂůŝĞƌZĠŐŝŽŶĂůhŶŝǀĞƌƐŝƚĂŝƌĞĚĞ34 
Lille, Lille, France; 35 
17 
Regional Reference Centre for Inherited Bleeding Disorders,
 
University Hospital of 36 
Parma, Parma, Italy; 37 
18
 Hôpital Cochin, Paris, France; 38 
19 
European Haemophilia Center, Paediatric Clinical Emergency Hospital Louis Turcanu, 39 
Timisoara, Romania; 40 
20 
Department of Disorders of Haemostasis and Internal Medicine, Institute of 41 
Haematology & Transfusion Medicine, Warsaw, Poland; 42 
21 
Haemophilia Centre, Azienda Universitaria Ospedaliera di Padova, Padova, Italy. 43 
  
3 
 
 44 
ŽƌƌĞƐƉŽŶĚŝŶŐĂƵƚŚŽƌ 45 
Angela M. Barbara 46 
Health Information Research Unit, CRL-134 47 
Clinical Epidemiology & Biostatistics 48 
McMaster University 49 
1280 Main St West 50 
Hamilton, ON  51 
Canada L8S 4K1 52 
Email: barbara@mcmaster.ca 53 
Tel: +1 905 525 9140 ext 22151 54 
Fax: +1 905-526-8447 55 
 56 
57 
  
4 
 
Abstract 58 
Background 59 
Development of inhibitors is the most serious complication in haemophilia A treatment. The 60 
assessment of risk for inhibitor formation in new or modified factor concentrates is traditionally 61 
performed in previously treated patients (PTPs). However, evidence on risk factors for and 62 
natural history of inhibitors has been generated mostly in previously untreated patients (PUPs). 63 
The purpose of this study was to examine cases of de novo inhibitors in PTPs reported in the 64 
scientific literature and to the EUropean HAemophilia Safety Surveillance (EUHASS) program, 65 
and explore determinants and course of inhibitor development.  66 
Methods 67 
We used a case-series study design and developed a case report form to collect patient level 68 
data; including detection, inhibitor course, treatment, factor VIII products used, and events that 69 
may trigger inhibitor development (surgery, vaccination, immune disorders, malignancy, 70 
product switch).  71 
Results 72 
We identified 18 publications that reported 43 inhibitor cases and 45 cases from 31 EUHASS 73 
centres. Individual patient data was collected for 55/88 (63%) inhibitor cases out of 12,330 74 
patients. The median (range) peak inhibitor titer was 4.4 (0.5  W 135.0), the proportion of 75 
transient inhibitors was 29% and only two cases of ten undergoing immune tolerance induction 76 
failed this treatment. In the two months before inhibitor development, surgery was reported in 77 
9 (16%) cases, and high intensity treatment periods reported in 7 (13%) cases.  78 
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Conclusions 79 
By studying the largest cohort of inhibitor development in PTPs assembled to date, we showed 80 
that inhibitor development in PTPs, is on average, a milder event than in PUPs. 81 
Keywords  82 
haemophilia A, factor VIII inhibitors, previously treated patients 83 
 84 
  85 
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Background 86 
The development of inhibitors, or neutralizing alloantibodies, continues to be the most 87 
serious challenge in the treatment of haemophilia A. High titre inhibitors interfere with factor 88 
Vlll replacement therapy, which often becomes completely ineffective, and are associated with 89 
high morbidity and mortality.[1] The highest risk of developing inhibitors in persons with 90 
haemophilia A occurs within the first 50 exposures days (ED) to factor VIII; a substantially lower 91 
risk has been observed in patients treated for more than 150 ED, who are commonly called 92 
previously treated patients (PTPs);[2] indeed, the rate of inhibitor development in PTPs has 93 
been estimated about three events (95% CI = 2-4) per thousand patient years.[3]  Due to this 94 
very low event rate in PTPs, our knowledge about risk factors for inhibitor development is 95 
mostly based on studies in previously untreated patients (PUPs), variably defined as patients 96 
with < 50 to 150 ED,[4,5] who are mostly young children with severe haemophilia A. On the 97 
other hand, current International Society on Thrombosis and Haemostasis (ISTH) and European 98 
Medicines Agency (EMA) / Food and Drug Administration (FDA) recommendations for 99 
assessment of the immunogenicity of new clotting factor concentrates indicate PTPs as the 100 
most suitable population.[4,6 W8] The concept behind this recommendation is that persons with 101 
haemophilia A previously tolerized to factor VIII will maintain tolerance to sufficiently similar 102 
new molecules, while they would react to those presenting important neo-antigens. 103 
For these reasons, many published reports reporting rates of inhibitors in PTPs are 104 
available only as part of phase III or IV studies, or as clinical observation reports. The main focus 105 
of these publications is to report, discuss and sometimes even compare (though comparisons 106 
are of course largely underpowered) rate of inhibitors with different molecules.[9 W11] Much 107 
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less is known about the natural history of inhibitors development in PTPs or about the 108 
triggering risk factors at play, which would be clinically important considering that the life 109 
expectancy of patients with haemophilia has doubled since the 1960s from less than 30 to more 110 
than 60 years of age,[12] and there is mounting evidence suggesting a higher incidence of 111 
inhibitors in PTPs aged 60 to 69 years.[13,14]  112 
To respond to this unmet clinical need, we have examined all cases of new inhibitors in 113 
PTPs identified from a systematic review of the literature and two international haemophilia 114 
registries.  115 
 116 
Methods 117 
We have designed the study as a case series, a design that has been recommended for 118 
studying rare adverse events. Indeed, this study design allows us to explore the characteristics 119 
of patients over a spectrum of cases, drawing loose inference from the underlying cohort and 120 
internal comparisons among cases with different characteristics. The design has high feasibility 121 
and is not resource intensive, and can be used as the first exploratory step in planning more 122 
robust future studies.[15,16] 123 
Identification of inhibitor cases 124 
Systematic Review 125 
Methods for the systematic review have been published elsewhere.[3]  126 
Haemophilia adverse events surveillance system 127 
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The European Haemophilia Safety Surveillance System (EUHASS) scheme collects 128 
information on adverse events related to haemophilia treatment, including the development of 129 
new inhibitors. For each inhibitor event, information is reported about the patient (age, gender, 130 
diagnosis, factor level) and the event (date, factor concentrate, additional blood products, 131 
assay, inhibitor levels, positive test cut-off). At the time of the study, EUHASS was in its fourth 132 
year.  We identified cases of new inhibitors reported to EUHASS. 133 
Case Report Form 134 
We drafted the Case Report Form (CRF) based on current knowledge of development of 135 
inhibitors. The CRF was intended to gather additional data that was not often contained in 136 
published reports. The draft was circulated for review and feedback to the authors of the 137 
publications included in the study and the European Haemophilia Network (EUHANET) network 138 
coordinators ?dŚĞZ&ǁĂƐƌĞǀŝƐĞĚĂŶĚĨŝŶĂůŝǌĞĚďĂƐĞĚŽŶƌĞǀŝĞǁĞƌƐ ?ĐŽŵŵĞŶƚƐ ?Supplemental 139 
Table 1).  140 
Data collection 141 
We took a multi-stage approach for contacting study authors and directors of 142 
haemophilia treatment centres participating in the EUHASS network to complete a CRF for each 143 
PTP with inhibitors. We included in the CRF all the known risk factors for inhibitor development 144 
in previously untreated patients (PUPs), as detailed in the Table 1 (see also Supplemental Table 145 
1). All respondents were invited to co-author the study report.  146 
Definitions 147 
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Haemophilia was defined as severe for plasma factor VIII levels <0.01 IU/mL; moderate 148 
haemophilia, for 0.01 to 0.05 IU/mL level of factor VIII; and mild haemophilia, for 0.06 to 0.40 149 
IU/mL of factor VIII. Previously treated persons (PTP) with haemophilia were defined as patients 150 
treated for 50 or more ED due to the lack of an accepted international definition for PTPs and 151 
variability in the definitions currently used to identify PUPs. However, we planned to report 152 
separately the number of cases falling into the following categories: 50-74, 75 to 149, and 153 
>=150 ED. High responders were defined as subjects with a peak titre >5.0 Bethesda Units 154 
(BU)/mL at diagnosis. Transient inhibitor was defined as an inhibitor that spontaneously 155 
resolved within six months without change in treatment regimen, i.e., without immune 156 
tolerance induction (ITI). As to the test used to diagnose inhibitors we accepted methods of 157 
Bethesda or its Nijmegen modification, and thresholds for negative values as reported by the 158 
authors or case contributors and the available information. Intense FVIII treatment period was 159 
as reported by the individual investigators who completed the CRF. Our guidance was that any 160 
treatment of 50 U/kg or more for three or more consecutive days would constitute an intense 161 
treatment period. 162 
Statistical Analysis 163 
We considered each of the cases for which we were provided CRF as one unit of a case 164 
series. We assumed data were missing at random both for inhibitors cases for which we did not 165 
get a CRF or information in the CRF was incomplete. Consequently, we described our cases 166 
series by calculating central tendencies as mean and standard deviation or median and range, 167 
or calculated proportions of cases with specific characteristics as appropriate. For each 168 
descriptive measure we reported the actual sample size. 169 
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 170 
Results 171 
The Preferred Reporting Items for Systematic Reviews (PRISMA) flow diagram provided 172 
the details of the case identification and data-gathering process (Figure 1). 173 
Systematic Review 174 
Detailed results of the systematic review are published elsewhere.[3] In summary, we 175 
identified 19 publications that reported 38 new inhibitors in PTPs with haemophilia A. 176 
Of the 38 identified inhibitors, we collected individual patient data for 29 (76%) inhibitor 177 
cases overall. The source population for the 29 inhibitors was 4,443 patients with haemophilia 178 
A (as calculated by summing up the number of patients included in the reports from which the 179 
29 cases were obtained); thus the inhibitor rate was 6.5 per 1000 patients (29/4,443). The data 180 
originated specifically from: 181 
x 13 (34%) CRFs completed by study authors for cases reported in nine publications [17 W182 
25]  183 
x 16 (42%) CRFs completed by extracting patient level information available from eight 184 
published reports. [26 W33]  185 
For nine inhibitors (24%) reported in three publications,[26,34,35] data extraction was not 186 
possible because the relevant publications included only aggregated summary data and the 187 
study investigators were unable to provide individual level data. One inhibitor was also 188 
reported to EUHASS. 189 
Haemophilia adverse events surveillance systems 190 
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There were 45 cases of new inhibitors in PTPs with severe haemophilia A reported to 191 
EUHASS in 31 of 75 participating European treatment centres. Nineteen (61%) of centres 192 
reporting inhibitors in the study provided CRF for their 26 cases (60% of all those reported to 193 
EUHASS, Figure 1).  The source population for the 26 inhibitors in EUHASS was estimated at 194 
7,887 (based on 31,551 patient years of follow-up reported by the centres observing the 26 195 
inhibitor cases  W data obtained directly from the EUHASS registry); thus the inhibitor rate was 196 
1.14 per 1,000 patient years. An approximate estimate comparable to the one calculated above 197 
from the published literature (based on the sum of the patients enrolled in each study) would 198 
be 3.3 per 1000 patients (26/7,887), not taking time into account.  199 
Patient characteristics 200 
In total, 55 cases were identified (29 in published literature, 26 reported to EUHASS). 201 
Severity of haemophilia A was available for 54 patients with inhibitors; the majority (48 of 54) 202 
had severe haemophilia; four patients had moderate haemophilia; and two patients had mild 203 
haemophilia. Thirty-six patients were reported to be White or Caucasian; one patient was Asian 204 
and another was Black. Information about ethnicity was missing for the other 18 patients. 205 
Inhibitor characteristics 206 
The inhibitor cases were diagnosed from 1998 (in the literature) to 2014 (reported to 207 
EUHASS).  Forty-one of fifty-four cases were diagnosed using the Bethesda assay, while for the 208 
remaining the Nijmegen modification or a combination of the two tests was used. Forty of 209 
forty-three cases used a cut-off for inhibitor of 0.6 BU/ml or lower, and three used a cut off of 210 
1.0 BU/ml. 211 
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ED at time of inhibitor detection was reported for 49 patients (of which, 43 had severe 212 
haemophilia A). Twenty-seven cases and (25 with severe haemophilia A) had 150 ED or more. 213 
Six patients were reported as PTPs by the hemophilia treatment centre to EUHASS (n = 2) or by 214 
the study authors in their publication (n = 4), but the numbers of EDs were not provided.  215 
Seventeen (15 with severe haemophilia) had reached 75 to 149 ED.  Five patients had between 216 
50 and 74 ED; three of these patients had severe haemophilia A, one had mild haemophilia A 217 
ĂŶĚƚŚĞŽƚŚĞƌƉĂƚŝĞŶƚ ?ƐƐĞǀĞƌŝƚǇǁĂƐŶŽƚƌĞƉŽƌƚĞĚŝŶƚŚĞůŝƚĞƌĂƚƵƌĞ.  218 
There were 24 high responders with severe haemophilia A. The peak titre levels for 219 
these patients ranged from 5.0 to 135 BU/mL (mean = 30.9). Fourteen of the cases were tested 220 
because of clinical signs and ten were clinically significant following diagnosis. The last known 221 
titre level of 10 high responders was more than 1 BU/mL. Further details regarding the 222 
inhibitors are reported in Tables 2-3.  223 
Frequency of occurrence of known risk factors for inhibitors development 224 
The age of the patient at first factor VIII (FVIII) exposure was known and reported for 31 225 
patients; age at first exposure ranged from six weeks to 55 years (mean = 12.7; SD = 14.7). Eight 226 
PTPs had a known family history of inhibitors. Information about the factor FVIII product used 227 
before and at inhibitor detection was available for 54 patients with inhibitors (Table 4).  228 
During their lifetime, 14 patients had a surgical procedure, 38 had switched FVIII 229 
products, 10 were vaccinated, five had an immune disorder, two had a malignancy, and 14 had 230 
a period of intense FVIII treatment (eight of these cases was associated to surgery; 231 
Supplemental Table 2) 232 
Data on risk factors during the two months prior to inhibitor detection was provided for 233 
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41 cases. Eighteen patients had at least one risk factor during that time period; eight had two (1 234 
had surgery and malignancy, 5 had surgery and intense FVIII treatment, 2 had surgery and 235 
switched FVIII products). 236 
Nine patients (of which 4 had > = 150 ED) had surgery. Six patients had severe 237 
haemophilia and had the following procedures: surgery for urinary cancer on the same day of 238 
inhibitor detection; total knee surgery nine days earlier; knee synovectomy on the same day; 239 
unspecified surgery 14 days earlier; dental surgery 21 days earlier; and prostatic adenoma and 240 
bladder polyps resection 43 days earlier. One patient had the inhibitor diagnosed on the day of 241 
surgery, which was complicated by sepsis; he had switched concentrate one month before 242 
surgery, and died on the day of surgery. The following details were reported for the other three 243 
non-severe PTPs: peripheral arterial occlusive disease bypass operation five days earlier; and 244 
prostate biopsies 20 days earlier (no details provided for one patient). Four severe PTPs and 245 
one with unknown severity switched FVIII (mean = 26 days, range = 1 to 60).  246 
 Two of these patients switched products 22 and 30 days prior to surgery (also counted 247 
above). One severe PTP was vaccinated, and one patient was diagnosed with an allergic 248 
reaction (urticaria).  Three patients received the following diagnoses of malignancy: prostate 249 
cancer; lymphoproliferative disorder; and mesothelioma. Only the patient with prostate cancer 250 
also had surgery and was counted above. Seven patients had intense treatment with FVIII (2 251 
had severed hemophilia A). The intense treatment was associated with surgery for five patients. 252 
One patient had severe ankle traumatic hemarthrosis and the other patient had a hip bleed 253 
following physical exercise.  254 
FVIII genotype was reported for 26 patients, of which 24 had severe haemophilia A 255 
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(Table 5).  256 
Clinical course 257 
Sixteen of 48 inhibitors were reported as spontaneously disappearing after six months 258 
without treatment. This group included the four patients with moderate haemophilia and 12 259 
patients with severe haemophilia. For these transient inhibitor cases, age varied from two to 61 260 
years and peak titre level ranged from 0.5 to 30 BU/mL. One inhibitor spontaneously resolved 261 
after one year. Clinical events following the diagnosis of the inhibitor were reported for 17 of 40 262 
patients, and included haemorrhage, decreased recovery, increased bleeding rate, and 263 
hemarthrosis.  264 
Twenty-one of 40 patients required a bypassing agent (rFVIIa or APCC). Patient ages 265 
spanned from 1 to 72 years (mean = 38). Peak titres ranged from 2.0 to 135 BU/mL; 16 patients 266 
were high responders. Twenty had severe haemophilia and one had mild haemophilia. 267 
Twelve of 40 patients were treated with immune tolerance induction. All had severe 268 
haemophilia A. Patients were aged 1 to 48 years (mean = 28), and all but the youngest patient 269 
had history of 150 ED or more. Nine patients were high responders with peak titres ranging 270 
from 7.0 to 135 BU/mL. For 10 of these 12 cases, ITI was successful.  271 
Of the 55 inhibitor patients, 26 were still alive. Of the 26 inhibitors patients reported to 272 
EUHASS, 23 were alive, and were still followed in the reporting centre. Data on live status for 273 
cases reported in the literature were available for only six patients, three of which were 274 
reported as alive and being followed by the centre. 275 
 276 
Discussion 277 
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This study reviewed a cohort of 55 cases of inhibitors which developed among 278 
approximately 12,000 previously treated patients with haemophilia A. To our knowledge, this is 279 
the largest ever cohort of inhibitor cases studied. By using a standardized case report form, we 280 
have been able to analyse the characteristics of these patients, the clinical course of their 281 
inhibitors and the role of risk factors. Inhibitor development is a complex multifactorial process. 282 
A number of risk factors have been identified in previously untreated patients, including non-283 
modifiable risk factors, specifically related to genetics, and modifiable or environmental risks 284 
factors. [36] Many previously published papers assessed the inhibitor rate in previously treated 285 
patients enrolled in phase III or phase IV studies,[7,22,24,25,37] or presented meta-analyses of 286 
such studies.[3,11,38] The main focus of these publications was to report, discuss and 287 
sometimes compare rate of inhibitors observed with specific molecules, to define their 288 
immunogenicity. Almost no attempt has been made before this study to explore the natural 289 
history of inhibitor development in previously treated patients or the triggering risk factors at 290 
play.  291 
In this study, most inhibitors developing in previously treated patients were of low titre, 292 
and disappeared spontaneously or after a course of immune tolerance induction. The risk 293 
conditions more frequently found shortly before inhibitor development were surgery and/or 294 
periods of intense treatment with factor VIII. Other conditions considered candidate risk factors 295 
for inhibitor development in previously untreated patients (product switching, vaccination, 296 
immune disorders, and malignancy) were found less frequently. We believe that the 297 
information about the frequency of occurrence of these characteristics is new, clinically 298 
relevant and confident it will trigger new research to explore causality. 299 
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The only risk factor that has been explored to some extent has been switching factor 300 
concentrate, a concept closely related to the one of molecule immunogenicity. Indeed, some 301 
reports have discussed whether switching from one concentrate to another (regardless of the 302 
specific products) increases the risk of inhibitor development in previously treated patients, as 303 
a result of molecular differences[6,9,10,39,40]. However, few of the studies were comparative 304 
in nature and, most importantly, none took into account other risk factors concurrent with 305 
factor concentrate switching mostly due to insufficient power[40]. By contrast, in the analysis of 306 
our cohort, we considered factor concentrate switching as one of several candidate risk factors, 307 
and we rigorously adopted a standard and narrow time window around the switch itself; when 308 
doing so, switching did not appear to have any important role. Indeed, our analysis confirmed 309 
that switching in the two months prior to development of an inhibitor occurred only in 5/52 310 
(10%) cases, of which only three (6%) had factor switching as a single candidate risk factor (the 311 
other two patients also had surgery during the two-month time period). 312 
One compelling reason for interest in inhibitor development in previously treated 313 
patients stems from the evidence suggesting higher incidence in patients aged 60 to 69 years 314 
[13,14].  This is very important considering the increasing  life expectancy of patients with 315 
haemophilia [12]. One might observe that only six of our cases fell in the above age range; the 316 
average age at inhibitor development in our case series was 36 years of age. This might cast 317 
doubts about the applicability of our findings to an older population; however, it must be noted 318 
that in our case series, mean (36 years) and median (35 years) almost overlapped, and the age 319 
range spanned from one to 72 years, suggesting that development of inhibitors in previously 320 
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treated patients is a random event, not correlated to age. The average age measured in our 321 
study likely overlaps with the average age of the underlying population at risk. 322 
While the major strength of our study is the relatively large number of occurrences of a 323 
very rare event, its main limitation is the absence of a control group. We adopted, for 324 
convenience and economy, a case series design. This design has been recommended for 325 
studying rare adverse events and combines the power and simplicity of the cohort method and 326 
the economy of the case-control method, while reducing confounding caused by factors that 327 
vary between people. This design would also make it possible to provide richer and more 328 
comprehensive information that is usually gathered with randomized controlled trials [15]. We 329 
expect that the novelty of the evidence we have been able to produce will prompt the 330 
leveraging of resources and willingness to participate in a future matched case-control study, 331 
which is needed to confirm or deny the causality of the association we have suggested. We 332 
strongly recommend that performing such a study is seriously considered by organizations in 333 
the field and we will work with the EUHASS network to assess feasibility of a nested case-334 
control study within their data collection framework. Other possible limitations of our study are 335 
the incompleteness of the case series, recall or detection biases. We have been able to gather 336 
data for 55 out of 87 cases (63%) reported in the literature and to EUHASS. While we 337 
acknowledge that the incompleteness of the case series might introduce bias, we have no 338 
specific reason to suspect that missing information is not random. Indeed, the authors and 339 
treatment centres tended to report either all or none of their patients. However, we found that 340 
the rate of inhibitors was about twice as high in the literature series as compared to the 341 
EUHASS data collection (6.5 versus 3.3 per 1000 patients). This difference can be explained by 342 
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either over-reporting due to recall bias in the literature series or underreporting of missed data 343 
in the EUHASS data collection. The former can introduce bias toward more or less severe cases 344 
being reported, the latter likely missing milder cases. In addition, the occurrence of events like 345 
surgery or need for intense treatment may have prompted more frequent inhibitor testing, 346 
thus increasing the chance of inhibitor detection and introducing potential bias. Finally, 347 
different thresholds for diagnosis of an inhibitor (Supplemental Table 3) and the process itself 348 
of estimating the denominator could be responsible for the observed difference.  On average, 349 
we consider our estimates quite conservative, and a more efficient data collection would 350 
possibly show an even less severe impact of inhibitors in the natural history of inhibitors in 351 
previously treated patients. In regards to inhibitor testing, a minor limitation would also be the 352 
non-standardization of the clinical and laboratory cut-off for inhibitor diagnosis (Supplemental 353 
Table 3); however, this is less relevant when the inhibitors of interest are clinically significant. 354 
Finally, we could not explore the possible role of ethnicity as a risk factor for insufficiency of 355 
data and did not collect information about the success/failure criteria for ITI or its duration. 356 
 357 
Conclusions 358 
The development of inhibitors in previously treated patients is a rare event, and we 359 
have now shown that it is usually milder than one might have predicted. Of course, each 360 
individual case deserves full support and care, and each case may be perceived as extremely 361 
severe for the patient, family and physicians experiencing the inhibitor. However, on a broader 362 
population perspective, the risk of development of inhibitors in previously treated patients 363 
might not be considered as relevant information for decisions about individual product 364 
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switches or tendering processes. Indeed, the benefits from the availability of new or cheaper 365 
products might outweigh the risk and impact of inhibitor development in previously treated 366 
patients. 367 
 368 
  369 
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Table 1:  Risk factors for inhibitor formation  560 
Modifiable:  Treatment 
x Factor VIII concentrate 
x Regimen (prophylaxis or on demand, dosage, interval) 
x Age of first exposure to FVlll concentrate 
 
Modifiable:  Trigger events or inflammatory responses 
 ? Surgery 
 ? Vaccination 
 ? Intense FVIII treatment periods 
 ? Infection or immunologic challenge  
 ? Switch in Factor VIII concentrate 
 
Non-modifiable:  Genetics 
 ? Ethnicity 
 ? Family history of inhibitors 
 ? Genotype 
 ? FVIII mutation 
 
 561 
  562 
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Table 2: Inhibitor characteristics of all patients by data source  563 
Characteristic N
1
 Mean (SD
2
) Median Range  
Age at inhibitor diagnosis (years)     
      Published literature 23 44 (18) 50 2 - 67 
      EUHASS registry 26 29 (18) 32 1.1 - 72 
      All 49 36 (19) 35 1.1 - 72 
Exposure days (ED) at diagnosis
3
     
      Published literature 25 150 (76) 120 50 - 363 
      EUHASS registry 24 280 (372) 150 55 - 1850 
      All 49 215 (273) 150 50 - 1850 
Titre level at first assessment, BU/mL
4
     
      Published literature 28 4.4 (8.4) 1.2 0.4  W 34.0 
      EUHASS registry 26 9.0 (14.2) 3.1 0.6  W 54.0 
      All 54 6.6 (11.6) 1.6 0.4  W 54.0 
Peak titre level, BU/mL     
      Published literature 25 11.1 (18.6) 2.4 0.5  W 75.0 
      EUHASS registry 26 20.0 (30.9) 7.5 0.8  W 135.0 
      All 51 15.7 (25.8) 4.4 0.5  W 135.0 
Last known titre level, BU/mL     
      Published literature 15 1.5 (2.6) 0.4 0.0  W 10.4 
      EUHASS registry 26 3.4 (8.6) 0.5 0.0  W 41.0 
      All 41 2.7 (7.0) 0.4 0  W 41.0 
Patient follow-up after inhibitor 
diagnosis, months
5
 
    
      Published literature 10 62 (59) 40.5 1 - 143  
      EUHASS registry 22 43.6 (42) 29.5 1 -166 
      All 32 49.3 (48.6) 29.5 1 - 166 
1
N=number of patients with available data 564 
2
SD=standard deviation  565 
3
5 patients had EDs of 50, 55, 59, 65 and 68 EDs at time of inhibitor detection; 17 patients had 75 to 143 566 
EDs, and 27 had >= 150 ED; ED were not reported for 6 patients  567 
4
BU/mL=Bethesda units per millilitre 568 
5
4 patients followed up for less than 1 year. 569 
 570 
  571 
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Table 3: Inhibitor characteristics of severe haemophilia A patients (n=48) 572 
Characteristic N
1
 Mean (SD
2
) Median Range  
Age at inhibitor diagnosis, years 43 34 (19) 36 1.1  W 72.0 
Exposure days (ED) at diagnosis
3
 43 227 (287) 150 55  W 1850 
Titre level at first assessment, BU/mL
4
 48 6.8 (12) 1.6 0.39  W 54.0 
Peak titre level, BU/mL 47 16.8 (26.3) 4.8 0.7  W 135.0 
Last known titre level, BU/mL 38 2.9 (7.1) 0.5 0.0  W 41.0 
Patient follow-up, months 30 50 (49) 30 1 - 166 
1
N=number of patients with available data 573 
2
SD=standard deviation  574 
3
3 patients with EDs of 55, 59 and 65 EDs at time of inhibitor detection; 15 patients had 75 to 143 EDs, 575 
and 25 had 150 ED or more; ED was not reported for 5 patients 576 
4
BU/mL=Bethesda units per millilitre. 577 
 578 
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Table 4: FVIII use before and at inhibitor detection  580 
Characteristic at inhibitor 
developent 
All  Severe only 150 ED or more 
Product used     
  Recombinant
1
, all 43
2
/54  37/48 21/27 
  Plasma-derived, all 11
3
/54  11/48 6/27 
Treatment indication     
   On demand  20/38  19/33 13/26 
   Prophylaxis 14/38) 12/33 8/26 
Surgical prophylaxis 4/38  2/33 2/26 
    
    
    
1
Top recombinant products: Kogenate (n=11), Refacto  AF/Zyntha (n=11), Advate (n=4), Helixate-Nexgen 581 
(n=3) 582 
2
Of the 43 patients, 14 were previously on another recombinant product, 10 were on a plasma-derived 583 
product and 1 patient switched from another unspecified product 584 
3
Of these 11 patients, 5 were previously on a different plasma-derived product, 2 were on a 585 
recombinant product, 2 never switched their product, 2 switched from other products, for which there 586 
are not available details  587 
  588 
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Table 5: Reported details of known FVIII genotype for 26 patients  589 
FVIII genotype details Severe 
only (n) 
Non-
severe 
(n) 
Intron 22 inversion 11 0 
Missense mutations, without further specifications  2 0 
c.971>G, pTrp33Gly 1 0 
Small inversion A 6960 6961 1 0 
Stop codon in exon 16 1 0 
Stop codon 1198 in exon 14  1 1 
p.Arg2169His 0 1 
p.Gly470Arg 0 1 
p.ArgR1997TrpW 1 0 
p. Val 253 Phe 1 0 
pR1997W 1 0 
p.Asn1460LysfsX2 (insertion of nucleotide A in a stretch of 9 A in 
exon 14; stop codon) 
 
1 0 
Arg3Gly 1 0 
Deletion R1696 (A3 domain) 1 0 
Complex gene rearrangement - not typical IVS 22 1 0 
 590 
